Fulcrum Therapeutics - FULC Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FULC shares.
View FULC analyst ratings or view top-rated stocks.

7 equities research analysts have issued 12 month price targets for Fulcrum Therapeutics' stock. Their FULC share price forecasts range from $11.00 to $35.00. On average, they predict the company's share price to reach $22.71 in the next twelve months. This suggests a possible upside of 269.9% from the stock's current price.
View analysts price targets for FULC or view top-rated stocks among Wall Street analysts.

Fulcrum Therapeutics' stock was trading at $17.69 on January 1st, 2022. Since then, FULC shares have decreased by 65.3% and is now trading at $6.14.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our FULC earnings forecast.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.57) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.07. The company had revenue of $4.94 million for the quarter, compared to the consensus estimate of $2.94 million. Fulcrum Therapeutics had a negative net margin of 1,000.65% and a negative trailing twelve-month return on equity of 54.55%. During the same quarter in the previous year, the business posted ($0.70) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV), Xeris Biopharma (XERS), CymaBay Therapeutics (CBAY), Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO).

(FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink served as the underwriters for the IPO.

Fulcrum Therapeutics trades on the NASDAQ under the ticker symbol "FULC."

Fulcrum Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (13.45%), RTW Investments LP (7.66%), BlackRock Inc. (5.33%), Vanguard Group Inc. (3.76%), Point72 Asset Management L.P. (2.87%) and VR Adviser LLC (2.31%). Insiders that own company stock include Christopher Morabito, Curtis Gale Oltmans, Diego Cadavid, James A Geraghty, Owen B Wallace, Peter G Thomson, Peter G Thomson, Robert J Gould and Robert J Gould.
View institutional ownership trends.

Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FULC stock can currently be purchased for approximately $6.14.

Fulcrum Therapeutics (NASDAQ:FULC) has a market capitalization of $319.59 million and generates $19.16 million in revenue each year. The company earns $-80,850,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

The company employs 104 workers across the globe.

Fulcrum Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.fulcrumtx.com. The company can be reached via phone at (617) 651-8851 or via email at christina.tartaglia@sternir.com.